BioSpace News Archive

Elligo Health Research is proud to welcome Michael Gibertini, Ph.D. , to its leadership team. Gibertini joins the team at the healthcare-enabling company as the new chief development officer and will develop new lines of business to support Elligo’s mission to bring clinical research as a care option to patients. An industry veteran, Gibertini brings over 30 years of experience to Elligo. His unique strength moldin

Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless cervical cancer detection test based on its patented biophotonic technology, announced today that it had submitted its protocol to FDA for a clinical study to support marketing of the LuViva® Advanced Cervical Scan in the United States. Under FDA’s Investigational Device Exemption guidelines, the Agency typically responds to companies

TScan Therapeutics, a biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies in oncology, today pre-published data on medRxiv.org identifying the precise targets of T cells isolated from COVID-19 convalescent patients. Immunodominant targets were shared among patients with the same human leukocyte antigen (HLA) type and were primarily located outside the spike protein.

Funding from Gilead will support creation of data map to systematically address the impact of the disease on Black and minority communities --

Recursion’s acquisition supplements its digital drug discovery vertical, further enabling its pipeline of four clinical and over 30 discovery programs

- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report current updates on the Company’s most important ongoing developments. The Company reports further significant and important progress has been made with remaining items for the upcoming regulatory filings in 2020 for the Company’s first in class innovative prostate drug Fexapotide Triflutate (FT). The Company has moved swiftly ahead on its regulatory marketing applicat

Publication of the Phase 2 U.S. study data show that RHB-102 (Bekinda ® ) 12mg delivers a clinically meaningful improvement in overall stool consistency response versus placebo in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), meeting the study’s primary endpoint -- In addition, the publication highlights that elevated baseline C-reactive protein (CRP) may be used to identify treatment responders in this complex disease, which lacks reliable predictive markers -- T

Nashville NeuroCare Therapy, the flagship neuroCare Centers of America clinic in Tennessee, today announced it is celebrating its 10-year anniversary of providing Transcranial Magnetic Stimulation (TMS) Therapy for depression, as the company continues to focus on leveraging innovative technologies and its personalized care approach of providing medication-free treatment options.

MJH Life Sciences™ today announced it will host “COVID-19: Race for a Vaccine,” a free, live, one-hour webinar, Thursday, July 30, at 6 p.m. EDT.

Immuneering Corporation today announced the company’s participation in the LifeSci Partners Private Company Virtual Summer Symposium, taking place August 4-5, 2020. The company’s co-founder and chief executive officer, Ben Zeskind, Ph.D., MBA, will present a corporate update to potential investors and strategic partners, among other various relevant audiences. The corporate update will cover recent and upcoming company milestones, as well as